Initial results from the anticipated Imbokodo trial are anticipated by 2021. Johnson & Johnson ( J&J ) has revealed that it has completed enrolment procedures for its efficacy trial of a HIV preventative vaccine from its subsidiary , Janssen . The phase IIb trial for the Imbokodo vaccine now has 2,600 female participants in the 18 - 49 age range from five African countries with high HIV rates . The vaccine will include mosaic immunogens from a variety of viral gene subtypes behind the HIV virus , with the aim of triggering an immune response . If a safe and effective vaccine can be created , it could help to significantly reduce the rate of new infections , according to J&J.
Johnson & Johnson ( J&J ) has revealed that it has completed enrolment procedures for its efficacy trial of a HIV preventative vaccine from its subsidiary , Janssen . The phase IIb trial for the Imbokodo vaccine now has 2,600 female participants in the 18 - 49 age range from five African countries with high HIV rates . The vaccine will include mosaic immunogens from a variety of viral gene subtypes behind the HIV virus , with the aim of triggering an immune response . If a safe and effective vaccine can be created , it could help to significantly reduce the rate of new infections , according to J&J.